Innovation helps health China Pfizer won the "Best Partner Award"

On April 13, the second phase of the Healthy Hainan-Lecheng Tour and "Never Ending" International Medicine and Equipment Exhibition organized by the Administration of the Boao Lecheng International Medical Tourism Pioneer Zone (hereinafter referred to as Lecheng Pioneer District) of Hainan Province was held as scheduled in Boao .

Contribute innovative wisdom and be the "best partner" of healthy China

The "Never Ending" International Innovative Medicine and Equipment Exhibition is not only a microcosm of the accelerated development of the Lecheng Pioneer Zone, but also an important window for multinational pharmaceutical companies to accelerate the introduction of innovative medicines that have not been listed in China to China.

Gu Gang, Secretary of the Party Committee and Director of the Lecheng Xianxing District Administration Bureau, said: "Last year, with the joint efforts of the provincial party committee and the provincial government leaders and multi-functional departments, with the support of many pharmaceutical and equipment companies, the first phase of the exhibition achieved satisfactory results.

With the big stage Equipments Fair, last year Pfizer demonstrated innovative drugs to be rapidly introduced into the Chinese market, for example, for the treatment of transthyretin amyloid polyneuropathy (ATTR-PN) of Vader whole ^® in China approved; treatment of adult wild type or genetic type transthyretin amyloidosis cardiomyopathy (ATTR-CM) of Vivoin heart ^® held in China starting; suitable for topical treatment of 2 years and older with mild to moderate atopic dermatitis patients of innovative small molecule non-hormonal prescription drugs outside Shutan Ming ^® is also home to the official listing.

Pfizer showcased a variety of innovative products and treatment solutions at this year's Pharmaceutical Equipment Exhibition, including:

Oncology

Lorlatinib for ALK-positive metastatic non-small cell lung cancer

Talazoparib for the treatment of BRCA mutant HER2-negative locally advanced or metastatic breast cancer patients

Sasanlimab for BCG-naïve NMIBC (non-muscular invasive bladder cancer)

 Inotuzumab Ozogamicin for the treatment of relapsed or refractory adult precursor B-cell acute lymphoblastic leukemia

Combined with low-dose cytarabine (LDAC) to treat Glasdegib in newly diagnosed adult patients with acute myeloid leukemia (AML) who are ≥75 years old or cannot use high-intensity induction chemotherapy due to comorbidities

Gemtuzumab Ozogamicin for the treatment of newly diagnosed CD33-positive acute myeloid leukemia (children and adults aged ≥1 month), and relapsed/refractory CD33-positive acute myeloid leukemia (children and adults aged ≥2 years)

Vaccine field

 13-valent pneumococcal polysaccharide conjugate vaccine for the prevention of 13 pneumococcal diseases of specific serotypes for all age groups (whole population)

 Group B meningococcal vaccine for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in people aged 10-25

A 4-valent meningitis polysaccharide conjugate vaccine for the prevention of epidemic cerebrospinal meningitis caused by ACWY meningococcus in people over 6 weeks of age

 20-valent pneumococcal polysaccharide conjugate vaccine for adults over 50 years old (adult indication)

 20-valent pneumococcal polysaccharide conjugate vaccine for 6 weeks to 5 years old (indications for children)

 A 5-valent meningitis polysaccharide conjugate vaccine for the prevention of epidemic cerebrospinal meningitis caused by meningococcus ABCWY in people aged 10-25

Anti-infection field

Cefaroline (ceftaroline) used for community-acquired pneumonia (CAP) in adults and children, and complex skin and soft tissue infections in adults and children

Cresemba (isaconazole) for the treatment of invasive aspergillosis and invasive mucor in adults

Inflammation and immunity

It is suitable for the treatment of moderate to severe atopic dermatitis patients who are 12 years old and above who do not respond well to external treatments or are not suitable for these treatments, including Abrocitinib to relieve itching

Ritlecitinib for the treatment of alopecia areata (including total alopecia and general alopecia) patients ≥12 years old

Cliborrol ointment for topical treatment of patients with mild to moderate atopic dermatitis 2 years old and above

Rare disease field

PF-06939926 for the treatment of Duchenne muscular dystrophy

Marstacimab for hemophilia A and B

Giroctocogene Fitelparvovec with hemophilia A indication

 Fidanacogene elaparvovec indicated for hemophilia B

PF-07256472 for the treatment of achondroplasia in children

Meglumine soft capsules for treating adult patients with stage I symptoms of transthyretin amyloidosis and delaying peripheral nerve damage

Cclofenac soft capsules suitable for the treatment of adult wild-type or genetic transthyretin amyloid cardiomyopathy (ATTR-CM) to reduce cardiovascular deaths and cardiovascular related hospitalizations

Internal Medicine Field

Tanezumab for treating moderate to severe osteoarthritis pain in adults and relieving cancer pain

Danuglipron for type 2 diabetes and obesity

Vupanorsen for hypertriglyceridemia and reducing the risk of cardiovascular events in patients with atherosclerotic cardiovascular disease

Accumulate China's innovation to keep pace with the world

Since entering the Chinese market for more than 30 years, Pfizer has always been committed to "becoming an important part of China's medical and health system" and has introduced more than 60 innovative drugs, covering five major areas including tumors, vaccines, anti-infection, inflammation and immunity, and rare diseases.

Malignant tumors have become one of the major public health problems that seriously threaten the health of the Chinese population.

Pfizer has been advancing the use of vaccines to treat a series of serious and even life-threatening diseases, including the most serious bacterial infections in infants, young children and the elderly.

The increase in bacterial antibiotic resistance and the lack of new antibiotics are currently the main global health problems related to bacterial infections.

In the field of inflammation and immunity, the incidence of atopic dermatitis in China is increasing year by year, especially for patients with moderate to severe atopic dermatitis, clinically, safe and effective treatments are urgently needed.

The field of rare diseases is a field that Pfizer has been paying attention to for a long time and has been continuously investing.

OA (osteoarthritis) is the most common type of arthritis, with a very high incidence in China.